Scientist II/Senior Scientist I, DMPK

Does it excite you to optimize DMPK properties, and do you have hands-on experience with LC-MS bioanalysis of complex molecular formats? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.

Your new position
Zealand Pharma is significantly expanding its global R&D capabilities and establishing new research units in Cambridge, MA to advance diverse drug modality capabilities in metabolic disease. As part of this expansion, you will play a central role in the DMPK group, advancing LC-MS capabilities and DMPK science within complex molecular formats. This is a unique opportunity for a scientist with strong scientific curiosity and technical expertise across mass spectrometry, pharmacokinetics, drug metabolism and bioanalysis.

We offer exciting responsibilities:

• Contribute to the development of DMPK discovery platforms and bioanalysis capabilities for complex drug modalities (e.g., antibodies, antibody-peptide conjugates and peptides)
• Execute the LC-MS bioanalysis workflow, from input to PK study design to method development, sample analysis and reporting of PK and exposure data
• Support PK and metabolite identification across discovery projects
• Design and conduct in vitro assays, such as metabolic stability experiments or other project-relevant DMPK assays
• Contribute to continuous improvement by adopting efficient, digital and automation-enabled approaches within DMPK workflows

Your profile
You bring strong technical expertise across the full LC-MS bioanalysis and PK workflow, along with scientific curiosity and sound judgment. You enjoy working in a collaborative, multidisciplinary environment and are motivated to help shape a new platform and research center from an early stage. You communicate scientific data and concepts clearly and work effectively across cross-functional project teams.

• PhD in pharmaceutical sciences, biochemistry, analytical chemistry, chemistry or a related scientific field with 0-3 years of relevant industry or postdoctoral experience; M.S. with approximately 3-6 years of relevant industry experience; or B.S./B.A. with approximately 5-8+ years of relevant industry experience
• Solid hands-on background in LC-MS bioanalysis and assay development
• Experience in PK study design, data interpretation, and translating DMPK insights into actionable project recommendations is an advantage
• Experience with bioanalysis of complex molecules such as peptides, antibodies and conjugates is an advantage
• Familiarity with ADME assays and metabolite ID for larger molecules, as well as experience with digital/automation-enabled bioanalysis and DMPK workflows, is an advantage

Your new team
You will join the Global DMPK department within Pharmacokinetics, Immunogenicity and Bioanalytical Sciences, working closely with cross-functional R&D stakeholders (e.g., Discovery, Translational, Toxicology, Clinical Pharmacology and Regulatory) to shape study strategies, interpret data, and communicate DMPK risks and recommendations.

Let’s bond and be bold
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.

Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.

Interested in bonding with us? Applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com.